Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAROTU)

Drug Name
RPKPfQwFwLL-NH2 Drug Info
Synonyms
96736-12-8; Antagonist D; [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P; CHEMBL501261; D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2; [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-Substance P; rPKPfQwFwLL-NH2; MFCD00076802; BDBM50260268; AKOS024456872; CA-1583; [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-Substance P, > (D-Arg1,D-Phe5,D-Trp7 inverted exclamation mark currency9,Leu11)-Substance P
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
25091011
TTD Drug ID
DMAROTU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Growth hormone secretagogue receptor 1 (GHSR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GHRP-2 DMKGH0R Growth hormone deficiency 5A61.3 Approved [2]
Ibutamoren DMFJ8LT Fibromyalgia MG30.01 Approved [3]
Macimorelin DMQYJIR Growth hormone deficiency 5A61.3 Approved [4]
Anamorelin DM6HXTS Carbohydrate metabolism disorder 5C51.Z Phase 3 [5]
TZP-101 DMOE582 Gastrointestinal disease DE2Z Phase 2b [6]
GTP-200 DM03NQS Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
RQ-00000005 DMBHN4K Frailty MG2A Phase 2 [8]
Tabimorelin DMNL9HO Growth hormone deficiency 5A61.3 Phase 2 [9]
Ibutamoren mesylate DMN2CM0 Growth hormone deficiency 5A61.3 Phase 2 [10]
Ipamorelin DM9PJZT Postoperative ileus DA91-DB30 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Growth hormone secretagogue receptor 1 (GHSR) TTWDC17 GHSR_HUMAN Inhibitor [1]

References

1 Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811.
2 GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68.
3 Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.
4 National Cancer Institute Drug Dictionary (drug id 735530).
5 Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73.
6 Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18.
7 Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346.
8 Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86.
9 Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
10 Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther. 2001 Jul;70(1):91-8.
11 Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6.